Basic Research in Cardiology

, Volume 80, Issue 3, pp 260–268 | Cite as

Dihydroergotoxine, an ergot alkaloid without marked hypotensive effect, improves blood flow and metabolism in the underperfused canine myocardium

  • R. Seitelberger
  • G. Raberger
Original Contributions
  • 21 Downloads

Summary

Regional myocardial blood flow was assessed in 6 anaesthetized dogs using radiolabelled microspheres. Lactate, H+, and O2 content were measured in arterial and local venous blood, obtained from the area supplied by the circumflex branch of the left coronary artery (LCX). Constriction of LCX by 67% led to considerable hemodynamic changes indicative of depressed global myocardial function. A significant release of lactate from the underperfused part of the left ventricle was recorded. Infusion of 0.7 μg/kg dihydroergotoxine over a period of 5 min induced a decrease in heart rate, left ventricular dp/dt max, and cardiac output, a sustained increase in total peripheral and femoral resistance and a transient increase in mean arterial blood pressure. Dihydroergotoxine markedly reduced lactate release and even, in some cases, induced lactate uptake and led to a significant increase in the endocardial blood flow both in the underperfused and normally perfused left ventricle.

It is concluded that dihydroergotoxine, due to its ability to reduce myocardial oxygen demand and owing to its α-sympatholytic activity, which is not accompanied by any marked decrease in arterial blood pressure, causes improvement in blood flow in the underperfused myocardium and a marked amelioration of the impaired metabolic processes.

Key words

dihydroergotoxine underperfused myocardium regional lactate balance radiolabelled microspheres myocardial oxygen demand 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Parratt JR (1981) The evidence for α-adrenoreceptors in the coronary circulation and their possible relevance to the physiological regulation of the myocardial blood flow. Basic Res Cardiol 76:485–493PubMedGoogle Scholar
  2. 2.
    Winniford MD, Filipchuk N, Hillis LD (1983) Alpha-adrenergic blockade for variant angina: a long-term, double-blind, randomized trial. Circulation 67:1185–1188PubMedGoogle Scholar
  3. 3.
    Berde B (1980) Ergot compounds: a synopsis. In: Goldstein M et al (eds) Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. Raven Press, New York, pp 3–23Google Scholar
  4. 4.
    Ulrich J, Jessen B, Siggaard-Andersen J (1973) Comparative effects of dihydroergotamine and hydergin® on the blood flow, capillary filtration rate and the capacitance vessels in the human calf studied by plethysmography. Angiology 24:657–663PubMedGoogle Scholar
  5. 5.
    Rothlin E, Cerletti A (1953) Experimentelle Untersuchungen über die cardiale Wirkung hydrierter Mutterkornalkaloide. Z ges exp Med 122:335–345PubMedGoogle Scholar
  6. 6.
    Rao DB, Norris JR (1972) A double-blind investigation of hydergine in the treatment of cerebrovascular insufficiency in the elderly. Hopkins Med J 130:317–324Google Scholar
  7. 7.
    Luke JC, Marien BN (1953) Hydrogenated ergot alkaloids in treatment of intermittent claudication. Canad MAJ 68:221–224Google Scholar
  8. 8.
    Frank N, Nakano J, Baldani CF (1956) The effect of hydergine on peripheral vascular disease. J Med Soc NJ 53:1–4Google Scholar
  9. 9.
    Freis ED, Stanton JR, Wilkins RW (1948) The effect of certain dihydrogenated alkaloids of ergot in hypertensive patients. Am J Med Sci 216:163–171Google Scholar
  10. 10.
    Seitelberger R, Schlappack O, Fasol R, Raberger G (1984) Comparison of the effects of dihydroergotamine and ergonovine on functional changes by β-adrenergic stimulation in normally and underperfused canine myocardium. J Cardiovasc Pharmacol 6:384–391PubMedGoogle Scholar
  11. 11.
    Seitelberger R, Schütz W, Raberger G (1984) Effects of dihydroergotamine (DHE) on blood flow and metabolism in the underperfused myocardium in anaesthetized dogs. Basic Res Cardiol 79:461–469PubMedGoogle Scholar
  12. 12.
    Mellander S, Nordenfelt I (1970) Comparative effects of dihydroergotamine and noradrenaline on resistance, exchange and capacitance functions in the peripheral circulation. Clin Sci 39:183–201PubMedGoogle Scholar
  13. 13.
    Müller-Schweinitzer E (1980) The mechanism of ergometrine-induced coronary arterial spasm: in vitro studies on canine arteries. J Cardiovasc Pharmacol 2:645–655PubMedGoogle Scholar
  14. 14.
    Hales JRS (1974) Radioactive microsphere techniques for studies of the circulation. Clin Exp Pharmacol Physiol Suppl 1:31–46Google Scholar
  15. 15.
    Hohorst HJ (1970) Bestimmung von L−(+)-Lactat mit Lactatdehydrogenase und NAD. In: Methoden der enzymatischen Analyse, Vol II. Verlag Chemie, Weinheim, pp 1425–1429Google Scholar
  16. 16.
    Holtz J, Held W, Sommer O, Kühne G, Bassenge E (1982) Ergonovine-induced constrictions of epicardial coronary arteries in conscious dogs: α-adrenoreceptors are not involved. Basic Res Cardiol 77:278–291PubMedGoogle Scholar
  17. 17.
    Feldman RL, Curry RC, Pepine CJ, Mehta J, Conti CR (1980) Regional coronary hemodynamic effects of ergonovine in patients with and without variant angina. Circulation 62:149–159PubMedGoogle Scholar
  18. 18.
    Klein LS, Simpson RJ, Stern R, Hayward JC, Foster JR (1982) Myocardial infarction following administration of sublingual ergotamine. Chest 82:375–376PubMedGoogle Scholar
  19. 19.
    Halmagyi D, Ivanyi J, Felkai B, Zsoter T, Tenyi M, Szucs Zs (1953) The effect of dihydroergotamine and hydergin on pulmonary arterial pressure in man. Scand J clin Lab Invest 5:85–89PubMedGoogle Scholar
  20. 20.
    Krause D (1954) Die Wirkung von Ergotamin und Hydergin auf die zentrale Kreislaufregulation. Naunyn-Schmiedebergs Arch exp Path Pharmak 222:212–214CrossRefGoogle Scholar
  21. 21.
    Cotton M de V, Moran NC, Stopp PE (1957) A comparison of the effectiveness of adrenergic blocking drugs in inhibiting the cardiac actions of sympathomimetic amines. J Pharmacol exp Ther 121:183–190PubMedGoogle Scholar
  22. 22.
    Gazes PC, Richardson JA, Woods EF (1959) Plasma catecholamine concentrations in myocardial infarction and angina pectoris. Circulation 19:657–661PubMedGoogle Scholar
  23. 23.
    Staszewska-Barczak J (1971) The reflex stimulation of catecholamine secretion during the acute stage of myocardial infarction in the dog. Clin Sci 41:419–439PubMedGoogle Scholar
  24. 24.
    Heusch G, Deussen A (1983) The effects of cardiac sympathetic nerve stimulation on perfusion of stenotic coronary arteries in the dog. Circ Res 53:8–15PubMedGoogle Scholar
  25. 25.
    Braunwald E (1971) Control of myocardial oxygen consumption. Amer J Cardiol 27:416–432CrossRefPubMedGoogle Scholar
  26. 26.
    Rothlin E (1947) The pharmacology of the natural and dihydrogenated alkaloids of ergot. Bull Schweiz Akad Med Wiss 2:249–273Google Scholar
  27. 27.
    Scherf D, Perlman A, Schlachman M (1949) Effect of dihydroergocornine on the heart. PSEBM 71:420–423Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag 1985

Authors and Affiliations

  • R. Seitelberger
    • 1
  • G. Raberger
    • 1
  1. 1.Pharmakologisches Institut der Universität WienWienAustria

Personalised recommendations